logo-loader
viewActinogen Medical Ltd

Actinogen moves to next stage of Alzheimer's treatment trials

Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may offer a novel new treatment of Alzheimer's disease.

Managing Director Dr Bill Ketelbey says the drug, which treats increased cortisol levels that may decrease cognitive ability, could be "an enormously valuable asset" even though it only treats, rather then cures Alzheimer's.

Quick facts: Actinogen Medical Ltd

Price: 0.026 AUD

ASX:ACW
Market: ASX
Market Cap: $29.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Meteoric Resources excited about 2020 program amid positive...

Meteoric Resources NL (ASX:MEI) managing director Andrew Tunks updates Proactive on why he believes Meteoric is so well positioned to reap positive gains from its 2020 exploration program. He talks about gold exploration being hot right now, with Australian and Brazilian gold prices at...

8 hours, 12 minutes ago

2 min read